Effect of granulocyte colony-stimulating factor in experimental methicillin resistant Staphylococcus aureus sepsis

BMC Infectious Diseases

Volumn 4, Issue , 2004, Pages

  Alp, Emine ^a   Gozukucuk, Suveyda ^a   Canoz, Ozlem ^a   Kirmaci, Beyhan ^a   Doganay, Mehmet ^a  

^a ERCIYES UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

POLYPEPTIDE ANTIBIOTIC AGENT; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TEICOPLANIN; VANCOMYCIN; ANTIINFECTIVE AGENT; GRANULOCYTE COLONY STIMULATING FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC THERAPY; ARTICLE; AUTOPSY; BACTERIUM COLONY; BACTERIUM CULTURE; BACTERIUM ISOLATE; CONTROLLED STUDY; HISTOPATHOLOGY; INFECTION CONTROL; INFECTION PREVENTION; INFLAMMATION; INOCULATION; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MOUSE; NONHUMAN; ORGAN CULTURE; SEPSIS; SURVIVAL RATE; TREATMENT FAILURE; ANIMAL; BAGG ALBINO MOUSE; DRUG COMBINATION; DRUG EFFECT; MICROBIOLOGY; PATHOGENICITY; PENICILLIN RESISTANCE; RANDOMIZATION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; TREATMENT OUTCOME;

ANIMALS; ANTI-BACTERIAL AGENTS; DRUG THERAPY, COMBINATION; GRANULOCYTE COLONY-STIMULATING FACTOR; MALE; METHICILLIN RESISTANCE; MICE; MICE, INBRED BALB C; RANDOM ALLOCATION; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN;

EID: 10144256541     PISSN: 14712334     EISSN: None     Source Type: Journal    
DOI: 10.1186/1471-2334-4-43     Document Type: Article

References (28)

1. Waldvogel FA: Staphylococcus aureus (including staphylococcal toxic shock). In: Principles and practise of infectious diseases fifth edition. Edited by: Mandell GL, Bennett JE, Dolin R. Churchill Livingstone, Philadelphia; 2000:2069-2092.
2. Esel , Doganay M, Alp E, Sumerkan B: Prospective evaluation of blood cultures in a Turkish university hospital: epidemiology, microbiology and patient outcome. Clin Microbiol Infect 2003, 9:1038-1044.
3. Wisplinghoff H, Seifert H, Tallent SM, Bischoff T, Wenzel RP, Edmond MB: Nosocomial bloodstream infections in pediatric patients in United States hospitals: epidemiology, clinical features and susceptibilities. Pediatr infect Dis J 2003, 22:686-691.
4. Mylotte JM, Tayara A, Goodnough S: Epidemiology of bloodstream infection in nursing home residents:evaluation in a large cohort from multiple homes. Clin Infect Dis 2002, 35: 484-1490.
5. Lautenschlager S, Herzog C, Zimmerli W: Course and outcome of bacteremia due to Staphylococcus aureus : evaluation of different clinical case definitions. Clin Infect Dis 1993, 16:567-573.
6. Conterno LO, Wey SB, Castelo A: Risk factors for mortality in Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol 1998, 19:32-37.
7. Harbarth S, Rutschmann O, Sudre P, Pittet D: Impact of methicillin resistance on the outcome of patients with bacteremia caused by Staphylococcus aureus. Arch Intern Med 1998, 158: 82-189.
8. Dale DC, Liles C, Summer WR, Nelson S: Review: granulocyte colony-stimulating factor-role and relationships in infectious diseases. J Infect Dis 1995, 172:1061-1075.
9. O'Reilly M, Silver GM, Greenhalgh DG, Gamelli RL, Davis JH, Hebert JC: Treatment of intra-abdominal infection with granulocyte colony-stimulating factor. J Trauma 1992, 33:679-682.
10. Yao L, Berman JW, Factor SM, Lowy FD: Correlation of histopathologic and bacteriologic changes with cytokine expression in an experimental murine model of bacteremic Staphylococcus aureus infection. Infect Immun 1997, 65:3889-3895.
11. Panlilio AL, Culver DH, Gaynes RP, Banerjee S, Henderson TS, Tolson JS, Martone WJ: Methicillin resistant Staphylococcus aureus in US hospitals, 1975-1991. Infect Control Hosp Epidemiol 1992, 13:582-586.
12. Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN, Beach M: SENTRY Partcipants Group. Survey of infections due to Staphylococcus species: frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific region for the SENTRY antimicrobial surveillance program, 1997-1999. Clin Infect Dis 2001, 32(Suppl 2):S114-32.
13. Voss A, Milatovic D, Wallrauch-Schwarz C, Rosdahl VT, Braveny I: Methicillin-resistant Staphylococcus aureus in Europe. Eur J Clin Microbiol Infect Dis 1994, 13:50-55.
14. Aygen B, Yoruk A, Yyldyz O, Alp E, Kocagoz S, Sumerkan B, Doganay M: Bloodstream infections caused by Staphylococcus aureus in a university hospital in Turkey: clinical and molecular epidemiology of methicillin-resistant Staphylococcus aureus. Clin Microb Infect 2004, 10:309-314.
15. Kallen A, Driscoll T, Thornton S, Olson P, Wallace M: Increase in community-acquired methicillin-resistant Staphylococcus aureus at a Naval Medical Center. Infect Control Hosp Epidemiol 2000, 21:223-226.
16. Gillan ER, Christensen RD, Suen Y, Ellis R, Ven C, van de, Cairo MS: A randomized, placebo-controlled trial of recombinant human granulocyte colony-stimulating factor administration in newborn infants with presumed sepsis: significant induction of peripheral and bone marrow neutrophilia. Blood 1994, 84:1427-1433.
17. Hustinx W, Benaissa-Trouw B, Van Kessel K, Kuenen J, Tavares L, Kraaijeveld K, Verhoef J, Hoepelman A: Granulocyte colony-stimulating factor enhances protection by anti-K1 capsular IgM antibody in murine Escherichia coli sepsis. Eur J Clin Invest 1997, 27:1044-1048.
18. Weiss M, Moldawer LL, Schneider EM: Granulocyte Colony-Stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood 1999, 93:425-439.
19. Wunderink R, Leeper K Jr, Schein R, Nelson S, DeBoisblanc B, Fotheringham N, Logan E: Filgrastim in patients with pneumonia and severe sepsis or septic shock. Chest 2001, 119:523-529.
20. Bedford Russell AR, Emmerson AJ, Wilkinson N, Chant T, Sweet DG, Halliday HL, Holland B, Davies EG: A trial of recombinant human granulocyte colony stimulating factor for the treatment of very low birthweight infants with presumed sepsis and neutropenia. Arch Dis Child Fetal Neonatal Ed 2001, 84:F172-F176.
21. Gough A, Clapperton M, Rolando N, Foster AV, Philpott-Howard J, Edmonds ME: Randomised placebo-controlled trial of granulocyte-colony stimulating factor in diabetic foot infection. Lancet 1997, 350:855-859.
22. van Linert ACM, Sijmons EA, Damen BFM, Heintz APM: Wound healing after radical vulvectomy and inguino-femoral lymphadenectomy: experience with granulocyte colony stimulating factor (filgrastim rmetHuG-CSF). Eur J Obstet Gynecol Reprod Biol 1995, 62: 17-219.
23. Root RK, Dale DC: Granulocyte Colony-Stimulating Factor and Granulocyte-Macrophage Colony-Stimulating Factor: Comparisons and potential for use in the treatment of infections in nonneutropenic patients. J Infect Dis 1999, 179(Suppl 2):S342-352.
24. Stephan F, Yang K, Tankovic J, Soussy CJ, Dhonneur G, Duvaldestin P, Brochard L, Brun-Buisson C, Harf A, Delclaux C: Impairment of polymorphonuclear neutrophil functions precedes nosocomial infections in critically ill patients. Crit Care Med 2002, 30:315-322.
25. Quezado Z, Parent C, Karzai W, Depietro M, Natanson C, Hammond W, Danner RL, Cui X, Fitz Y, Banks SM, Gerstenberger E, Eichacker PQ: Acute G-CSF therapy is not protective during lethal E. coli sepsis. Am J Phsiol Regulatory Integrative Comp Physiol 2001, 281:R1177-R1185.
26. Karzai W, von Specht BU, Parent C, Haberstroh J, Wollersen K, Natanson C, Banks SM, Eichacker PQ: G-CSF during Esherichia coli versus Staphylococcus aureus pneumonia in rats has fundamentally different and opposite effects. Am J Respir Crit Care Med 1999, 159:1377-82.
27. Root RK, Lodato RF, Patrick W, Cade JF, Fotheringham N, Milwee S, Vincent JL, Torres A, Rello J, Nelson S: Pneumonia Sepsis Study Group. Multicenter, double-blind, placebo-controlled study of the use of filgrastim in patients hospitalised with pneumonia and severe sepsis. Crit Care Med 2003, 31:367-373.
28. Smith WS, Sumnicht GE, Sharpe RW, Samuelson SD, Nillard FE: Granulocyte Colony-Stimulating Factor versus placebo in addition to penicillin G in a randomised blinded study of Gram-negative pneumonia sepsis: analysis of survival and multisystem organ failure. Blood 1995, 86:1301-1309.